Format

Send to

Choose Destination
Vaccine. 1999 Feb 5;17(5):454-8.

Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.

Author information

1
Department of Medical Microbiology, Lund University, Sweden.

Abstract

Group B streptococcus (GBS), a bacterium with polysaccharide capsule, is the major cause of sepsis and meningitis in early infancy. Recent work has indicated that immunity to GBS infection can be elicited by the surface proteins Rib and alpha, either of which is expressed by most GBS strains causing invasive infections. Here we show that a bivalent vaccine, composed of purified Rib and alpha mixed with aluminum hydroxide (alum), an adjuvant accepted for human use, elicits an antibody response to each of the two antigens. Moreover, the bivalent vaccine was found to protect against experimental infection with GBS strains representing the four classical serotypes. Our results represent an encouraging step towards the development of a human GBS vaccine based on pure protein antigens.

PMID:
10073723
DOI:
10.1016/s0264-410x(98)00218-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center